Form 8-K - Current report:
SEC Accession No. 0001193125-25-063253
Filing Date
2025-03-26
Accepted
2025-03-26 08:21:16
Documents
13
Period of Report
2025-03-25
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d937606d8k.htm   iXBRL 8-K 27907
  Complete submission text file 0001193125-25-063253.txt   150223

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA whwk-20250325.xsd EX-101.SCH 2841
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE whwk-20250325_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE whwk-20250325_pre.xml EX-101.PRE 11255
15 EXTRACTED XBRL INSTANCE DOCUMENT d937606d8k_htm.xml XML 3662
Mailing Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960
Business Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960 551-321-2234
Whitehawk Therapeutics, Inc. (Filer) CIK: 0001422142 (see all company filings)

EIN.: 611547850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38560 | Film No.: 25770268
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)